BARDA Official Says Trial Network For Antibiotics Needs Industry Buy-In

A BARDA official touted a proposed clinical trial network for antibiotics at an FDA workshop Monday (July 18) that would allow companies to share patient control groups in order to decrease costs for phase III clinical trials and encourage new antibiotic drug development, but says the infrastructure's cost and the need for industry buy-in remain challenges. FDA's drug center head told House lawmakers last month that it would take decades of work for antibiotic development to catch up with antibiotic...